Pacritinib in CMML

Official title

Pacritinib in Combination With Azacitidine in Patients With Chronic Myelomonocytic Leukemia

Overview

This is a phase 1/2 trial of pacritinib in combination with azacitidine in patients with Chronic Myelomonocytic Leukemia (CMML). Patients will be newly diagnosed or previously treated but could not have received a prior JAK inhibitor. Patients who have previously been treated with a hypomethylating agent (HMA) must have received ≤ 1 cycle. Pacritinib will be initially tested at a dose of 200mg twice daily (dose level 0) in combination with azacitidine 75mg/m2, which can be administered subcutaneously or intravenously, for 7 days in a 28-day cycle. If there are 2 DLTs in the first 6 patients, there will be a dose escalation to pacritinib 100mg twice daily (dose level -1) and an additional 6 patients will be enrolled. Based on the phase 1, 3+3 dose de-escalation design, 6-12 patients will be enrolled in the phase 1 portion. After the completion of phase 1 and identification of the recommended phase 2 dose (RP2D), the trial will then proceed to phase 2 which will employ a Simon two stage design. This portion will include the 6 patients enrolled during the phase 1 portion at the MTD. An interim analysis for futility will occur. If 3 or fewer patients have had a clinical benefit (CB) or better, as defined by 2015 MDS/MPN IWG criteria, the PI and DSMC will meet to discuss the totality of the evidence and determine if the trial shall proceed. In the second stage, an additional 12 patients will be enrolled.

Interventions

• Drug Pacritinib
  Participants will take Pacritinib 100 mg - 200mg BID for each 28 day cycle
• Drug Azacitidine
  Azacitidine 75mg/m\^2 will be administered IV or SQ QD D1-7 of each 28 day cycle

Primary outcome measures

• Dose-limiting toxicity of Pacritinib in combination with Azacitidine [Time frame: at the end of one 28-day cycle]
• Proportion of participants that achieve clinical benefit or better measured using 2015 MDS/MPN IWG Criteria [Time frame: 24 weeks (6 cycles, each cycle is 28 days)]
• Overall Response Rate (ORR) to measure clinical benefit [Time frame: 24 weeks (6 cycles, each cycle is 28 days)]

Secondary outcome measures (8)

• Number of Adverse events Grade 3 or higher measured using NCI CTCAE Version 5.0 [Time frame: up to 30 days after last study dose (up to 6 cycles, each cycle 28 days)]
• Duration of Response (DOR) to measure efficacy [Time frame: up to 24 months]
• Overall Survival (OS) to measure efficacy [Time frame: up to 24 months]
• Disease Free Survival (DFS) to measure efficacy [Time frame: up to 24 months]
• Change in Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN-SASF TSS) [Time frame: Baseline and after 3 and 6 cycles of therapy, each cycle is 28 days]
• Percentage of patients achieving "very much" or "much" in the Patient Global Impression of Change (PGIC) [Time frame: Baseline and after 3 and 6 cycles of therapy, each cycle is 28 days]
• Change in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Score [Time frame: Baseline and after 3 and 6 cycles of therapy, each cycle is 28 days]
• Change in Palpable Spleen Size [Time frame: Baseline and after 3 and 6 cycles of therapy, each cycle is 28 days]

Eligibility criteria

Inclusion criteria

• Participants must be ≥18 years of age at time of signing the Informed Consent Form (ICF).
• Participants must voluntarily sign an ICF.
• Participants must have a pathologically confirmed diagnosis of chronic myelomonocytic leukemia per World Health Organization (WHO) or International Consensus Classification (ICC)
• Participants must be JAK inhibitor naïve.
• Participants may be hypomethylating agent (HMA) naïve or can be treated with up to one prior cycle.
• Participants must have either proliferative CMML (WBC ≥13 x 109/L) or have intermediate-2 or high risk CMML by the clinical/molecular CMML-specific prognostic scoring system (CPSS-Mol).
• Participants must have a life expectancy of at least 24 weeks per investigator.
• ECOG performance status ≤ 3.
• Females of reproductive potential should use effective contraception during treatment with azacitidine and for 6 months after the last dose and males with female partners of reproductive potential should use effective contraception during treatment with azacitidine and for 3 months after the last dose.
• Male participants should agree to use an adequate method of contraception starting with the first dose of study therapy through 90 days after the last dose of study therapy.
• Must have adequate organ function as demonstrated by the following:

• Serum total bilirubin ≤ 2.0 x upper limit of normal (ULN) unless considered due to leukemic organ involvement, Gilbert's syndrome, or hemolysis.
• Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3.0 x ULN.
• Creatinine clearance (CrCl) of ≥30 mL/min.
• PT or INR <=1.5x ULN and PTT or aPTT <=1.5x ULN.
• ANC >= 500 cells/μL.
• Ability to adhere to the study visit schedule and all protocol requirements.
• Ability to understand and the willingness to sign a written informed consent.

Exclusion criteria

• Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 2 weeks or within 5 half-lives of the prior investigational agent, whichever is shorter, of the first dose of treatment.
• Active Graft Versus Host Disease (GVHD), or any GVHD requiring treatment with immunosuppression, with the exception of topical steroids and systemic steroids at a dose equivalent to prednisone 10mg or less and at a stable or decreasing dose. Any GVHD treatment (including calcineurin inhibitors) must be discontinued at least 28 days prior to Day 1 of study treatment.
• Systemic treatment with a strong CYP3A4 inhibitor or a strong CYP450 inducer within 14 days prior to treatment Day 1 (see Appendix 13.7 and 13.8 for a list of CYP3A4 inhibitors and CYP450 inducers, respectively). Shorter washout periods may be permitted with approval of the Study Chair, provided that the washout period is at least five half-lives of the drug prior to treatment Day 1.
• Other invasive malignancies within the last 3 years, except curatively treated non-melanoma skin cancer, localized prostate, cervical cancer, and any curatively treated carcinoma in situ.
• Presence of active serious infection.

• If a patient is identified to have COVID-19 during the screening period, participants may be considered eligible if in the opinion of the investigator there are no COVID-19 sequlae that may place the patient at a higher risk of receiving investigational treatment.
• Any serious, unstable medical or psychiatric condition that would prevent, (as judged by the Investigator) the patient from signing the informed consent form or any condition, including the presence of laboratory abnormalities, which places the patient at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.
• Known history of uncontrolled human immunodeficiency virus (HIV).
• Significant recent bleeding history defined as NCI CTCAE grade ≥2 within 3 months prior to treatment Day 1, unless precipitated by an inciting event (e.g., surgery, trauma, or injury).
• Systemic treatment with medications that increase the risk of bleeding, including anticoagulants, antiplatelet agents (except for aspirin dosages of ≤100 mg per day), anti-vascular endothelial growth factor (anti-VEGF) agents, and daily use of COX-1 inhibiting Non-steroidal anti-inflammatory drugs (NSAIDs) within 14 days prior to treatment Day 1.
• Any history of CTCAE grade ≥2 cardiac conditions within 6 months prior to treatment Day 1. Patients with asymptomatic grade 2 non-dysrhythmia cardiovascular conditions may be considered for inclusion, with the approval of the Study Chair, if stable and unlikely to affect patient safety.
• Heart failure other than NYHA class I (asymptomatic, without limitation).
• QT corrected by the Fridericia method (QTcF) prolongation >480 ms or other factors that increase the risk for QT interval prolongation (e.g., hypokalemia \[defined as serum potassium <3.0 mEq/L that is persistent and refractory to correction\], or history of long QT interval syndrome).
• Known active systemic hepatitis B, or C infection requiring therapy or known cirrhosis.
• Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or pharmaceutical sponsor staff directly involved with this trial, unless prospective IRB approval (by chair or designee) is given allowing exception to this criterion for a specific participant.
• Organ transplant recipients other than bone marrow transplant.
• Women who are pregnant or lactating.
• Patient with known gastrointestinal (GI) disease or prior GI procedure that could interfere with the oral absorption or tolerance of pacritinib, including difficulty swallowing, are not eligible.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

N/A

Model

Sequential

Masking

Open label

Primary purpose

Treatment

Study locations

United States · 1 center

• The Mount Sinai Hospital — New York

Identifiers

NCT: NCT06159491 · GCO 23-1514

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗